GlassScriptPhysician profile
Douglas John Thompson
NPI 1669541983
$5,267.72
in general payments reported to CMS, 2019-2025
47 companies · $2,059 in 2025
The $2,059 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $143 · 2020: $41.67 · 2021: $345 · 2022: $631 · 2023: $889 · 2024: $1,160 · 2025: $2,059.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,897 · Education: $211.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,896.82 |
| Education | $211.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $449.50 | 2019-2025 | |
| Daiichi Sankyo INC. | $431.23 | 2020-2025 | Enhertu, Injectafer |
| Pfizer INC. | $395.79 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $321.73 | 2021-2025 | Opdivo, Augtyro, Krazati |
| Janssen Biotech, INC. | $283.12 | 2023-2025 | Tecvayli, Darzalex, Erleada |
| Celgene Corporation | $245.57 | 2024-2025 | Reblozyl, Pomalyst, Opdualag |
| Astrazeneca Pharmaceuticals LP | $235.07 | 2021-2025 | Enhertu, Tagrisso, Imfinzi |
| Glaxosmithkline, LLC. | $234.27 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Seagen INC. | $233.02 | 2022-2025 | Adcetris, Padcev |
| Amgen INC. | $231.39 | 2020-2023 | Kyprolis, Nplate, Vectibix |
| Puma Biotechnology, INC. | $156.67 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $138.44 | 2019-2025 | Keytruda, Keytruda Qlex |
| Jazz Pharmaceuticals INC. | $110.79 | 2023-2025 | |
| Genzyme Corporation | $107.67 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $105.09 | 2019-2024 | Libtayo |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $95.99 | 2024-2025 | Braftovi, Mektovi, Lorbrena |
| Exelixis INC. | $90.51 | 2019-2023 | Cabometyx |
| Incyte Corporation | $89.35 | 2022-2023 | Monjuvi |
| Genentech USA, INC. | $88.60 | 2024-2025 | Polivy, Venclexta |
| Beigene USA, INC. | $85.30 | 2023-2025 | Brukinsa, Tevimbra |
| Astellas Pharma US INC | $85.01 | 2024-2025 | Padcev, Xtandi |
| Lilly USA, LLC | $78.95 | 2019-2025 | Jaypirca, Verzenio |
| Bayer Healthcare Pharmaceuticals INC. | $76.86 | 2021-2025 | |
| Adc Therapeutics America, INC. | $75.22 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $74.47 | 2024-2025 | Monoferric, Cosela |
| Takeda Pharmaceuticals U.S.A., INC. | $66.19 | 2024 | Ninlaro |
| Gilead Sciences, INC. | $65.91 | 2025 | Trodelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.30 | 2021 | |
| Karyopharm Therapeutics INC. | $52.27 | 2024-2025 | Xpovio |
| Rigel Pharmaceuticals, INC. | $45.50 | 2024-2025 | Rezlidhia, Gavreto, Tavalisse |
| Pharmaessentia USA Corporation | $38.85 | 2023-2025 | Besremi |
| Abbvie INC. | $36.63 | 2025 | |
| Stemline Therapeutics INC. | $36.34 | 2024 | Elzonris |
| Kite Pharma, INC. | $36.20 | 2022-2025 | Yescarta |
| Beone Medicines USA, INC. | $34.38 | 2025 | Brukinsa |
| G1 Therapeutics, INC. | $33.47 | 2022-2023 | Cosela |
| Tempus Ai, INC | $29.79 | 2025 | Xt Cdx |
| Mirati Therapeutics, INC. | $26.80 | 2023 | Krazati |
| Novocure INC. | $24.02 | 2025 | Optune Lua (Novottf-200t) |
| Argenx US, INC. | $23.62 | 2023 | Vyvgart Hytrulo |
| Deciphera Pharmaceuticals INC. | $22.99 | 2023 | Qinlock |
| Pharmacyclics LLC, An Abbvie Company | $22.75 | 2022 | |
| Medtronic, INC. | $22.47 | 2024 | Osteocool Rf Ablation System |
| Emd Serono, INC. | $22.41 | 2023 | Bavencio |
| Octapharma USA, INC. | $19.20 | 2024 | Octagam Immune Globulin (Human) |
| Adaptive Biotechnologies Corporation | $16.38 | 2023 | Clonoseq |
| Janssen Pharmaceuticals, INC | $12.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.